ArticleFrontiers in public health2026

First-line enfortumab vedotin-pembrolizumab versus nivolumab plus gemcitabine-cisplatin in metastatic urothelial cancer: a cost-effectiveness study.

Haojie Ying et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.